adenosine diphosphate has been researched along with 2019 Novel Coronavirus Disease in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 7 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alfaro, E; Cubillos-Zapata, C; Díaz-García, E; Galera, R; García-Rio, F; García-Tovar, S; López-Collazo, E; Mangas, A; Nanwani-Nanwani, K; Pérez-de-Diego, R; Rodríguez-Gallego, C; Ruíz-Hernández, JJ; Solé-Violán, J; Van-Den-Rym, A; Zamarrón, E | 1 |
| Alsheik, A; Friebel, J; Haghikia, A; Jakobs, K; Kränkel, N; Landmesser, U; Puccini, M; Rauch-Kröhnert, U; Reinshagen, L; Rroku, A; Wilde, AB | 1 |
| Andrejew, R; Aoki, V; Battastini, AM; Benard, G; Custódio, RWA; de Brito, CA; Duarte, AJDS; Figueiró, F; Glaser, T; Goffinet, C; Kazmierski, J; Oliveira, LM; Pietrobon, AJ; Sato, MN; Scholl, JN; Teixeira, FME; Turdo, AC; Ulrich, H; Yendo, T | 1 |
| Amoafo, EB; Entsie, P; Kang, Y; Liverani, E; Schöneberg, T | 1 |
| Anmangandla, A; Bagde, SR; Drown, BS; Fromme, JC; Hergenrother, PJ; Jana, S; Lin, H; Peng, K; Wallace, SD; Xu, J | 1 |
| Beckenkamp, LR; Korb, VG; Schultz, IC; Wink, MR | 1 |
| Kanthi, Y; Knight, JS; Pinsky, DJ; Zuo, Y | 1 |
2 review(s) available for adenosine diphosphate and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
The Signaling Pathway of the ADP Receptor P2Y
Topics: Adenosine Diphosphate; Animals; Blood Platelets; COVID-19; Humans; Immune System; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Signal Transduction | 2023 |
A Systematic Review of the Role of Purinergic Signalling Pathway in the Treatment of COVID-19.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; COVID-19; COVID-19 Drug Treatment; Humans; Nucleosides; Receptors, Purinergic; SARS-CoV-2 | 2023 |
5 other study(ies) available for adenosine diphosphate and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Role of CD39 in COVID-19 Severity: Dysregulation of Purinergic Signaling and Thromboinflammation.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Apyrase; Biomarkers; Blood Platelets; Cell Hypoxia; COVID-19; Critical Care; Female; Humans; Influenza A virus; Influenza, Human; Length of Stay; Male; Middle Aged; Platelet Activation; Prognosis; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y; SARS-CoV-2; Severity of Illness Index; Signal Transduction; Thromboinflammation; Ticagrelor | 2022 |
Disease Severity in Moderate-to-Severe COVID-19 Is Associated With Platelet Hyperreactivity and Innate Immune Activation.
Topics: Adenosine Diphosphate; Blood Platelets; COVID-19; Humans; Immunity, Innate; Inflammation; Interleukin 1 Receptor Antagonist Protein; Interleukin-6; RNA, Viral; SARS-CoV-2; Severity of Illness Index | 2022 |
Dysfunctional purinergic signaling correlates with disease severity in COVID-19 patients.
Topics: Adenosine; Adenosine Diphosphate; Adenosine Triphosphate; COVID-19; Humans; Purines; Severity of Illness Index; Signal Transduction | 2022 |
A Fluorescence Polarization Assay for Macrodomains Facilitates the Identification of Potent Inhibitors of the SARS-CoV-2 Macrodomain.
Topics: Adenosine Diphosphate; Adenosine Diphosphate Ribose; COVID-19; Fluorescence Polarization; Humans; SARS-CoV-2 | 2023 |
New (re)purpose for an old drug: purinergic modulation may extinguish the COVID-19 thromboinflammatory firestorm.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Dipyridamole; Drug Repositioning; Extracellular Traps; Humans; Pandemics; Phosphodiesterase Inhibitors; Pneumonia, Viral; Purinergic Agents; SARS-CoV-2; Thrombosis | 2020 |